№ files_lp_3_process_7_056858
File format: docx
Character count: 2438
File size: 62 KB
Official Freedom of Information response presenting statistical data on newly treated dermatology patients and psoriasis cases across two hospital sites for a defined three-month period.
Date:
21/01/2026
Organisation:
Bedfordshire Hospitals NHS Foundation Trust
Sites:
Bedford site; Luton site
Department:
Dermatology Department
Legislation:
Freedom of Information Act 2000
Reporting period:
October–December 2025
Definition of new patient:
Patient receiving any of the listed treatments for the first time during the reporting period, including those previously treated in 2024 or earlier years
Treatments listed:
Adalimumab (Humira and biosimilars); Etanercept (Enbrel and biosimilars); Infliximab (Remicade and biosimilars); Ustekinumab (Stelara and biosimilars); Apremilast (Otezla); Bimekizumab (Bimzelx); Brodalumab (Kyntheum); Certolizumab (Cimzia); Deucravacitinib (Sotyktu); Dimethyl Fumarate (Skilarence); Guselkumab (Tremfya); Ixekizumab (Taltz); Risankizumab (Skyrizi); Secukinumab (Cosentyx); Spesolimab (Spevigo); Tildrakizumab (Illumetri)
Data categories:
Total Dermatology Department; Psoriasis
Data format:
Numerical counts, including ranges (1–5)
Intellectual property notice:
Subject to Re-use of Public Sector Information Regulations 2015
Author:
FOI Officer
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2024
Region / City:
Australia
Topic:
Psoriasis Treatment
Document Type:
Patient Handout
Organization:
Victorian Government, Department of Health
Author:
Not specified
Target Audience:
Patients with mild plaque psoriasis
Period of validity:
Not specified
Approval Date:
March 2024
Amendment Date:
Not specified
Cost Information:
Free consultation; medicine costs vary based on Medicare and PBS status
Eligibility:
Adults aged 18 or older with mild plaque psoriasis
Additional Support:
Websites provided for more information
Complaint Process:
Information on complaints available at www.health.vic.gov.au/feedback-and-complaints
Safety Net Information:
Medications not included in PBS Safety Net
Consultation Details:
Private consultation with a pharmacist
Prescription Information:
Medicines under PBS or full price for non-listed items
International Students:
Eligible based on specific countries
Consent Process:
Provided during consultation
Health Advice:
Self-care and lifestyle tips included
Expected Outcome:
Symptoms should improve within 2-4 weeks
What to do if symptoms worsen:
Visit a doctor if no improvement or worsening of condition
Contact:
[email protected]
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Year:
2025
Region / City:
Ternopil
Theme:
Psoriasis, Nursing, Quality of Life, Chronic Disease
Organization / Institution:
I. Horbachevsky Ternopil National Medical University
Author:
Viktoriya Zhura
Target Audience:
Healthcare professionals, nursing educators, researchers
Period of Action:
2025
Approval Date:
2025
Date of Changes:
-
Year:
Not specified
Region / City:
Not specified
Topic:
Clinical trial design, sample size estimation
Document type:
Educational material, study design guide
Author:
Not specified
Target audience:
Clinical researchers, study designers
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Research field:
Genetic epidemiology
Topic:
Genetic association analysis of psoriasis and psoriatic arthritis
Document type:
Research methods and supplementary materials description
Dataset:
Immunochip dataset
Genotyping centres:
Wellcome Trust Sanger Institute; Centre for Public Health Genomics at the University of Virginia; Arthritis Research UK Centre for Genetics and Genomics at the University of Manchester; University of Queensland Diamantina Institute; Trinity Translational Medicine at the University of Dublin
Genotyping software:
GenomeStudio Data Analysis Software Platform (Genotyping Module v1.8.4)
Quality control tools:
PLINK v1.07; EIGENSOFT v4.2; flashpca
Statistical methods:
Identity-by-descent analysis; principal component analysis; logistic regression; Hardy–Weinberg equilibrium filtering
Genetic markers:
SNPs from Immunochip array
Genomic region of interest:
Major Histocompatibility Complex (MHC)
Genes analyzed:
HLA-C; HLA-B; HLA-A
Phenotypes studied:
Psoriasis; Psoriatic arthritis
Population reference datasets:
HapMap3 CEU; CHB; JPT; YRI
Variables analyzed:
Allele frequency; genotype call rate; heterozygosity; age of disease onset
Associated amino acid position:
Position 45 of HLA-B
RFP Title:
Frankfort Riverfront Visioning and Strategic Plan
Bid/Contract Number:
2526001-83
Issuance Date:
October 24, 2025
Proposals Due Date:
December 10, 2025, 2:00 p.m. EST
Questions Due Date:
December 3, 2025
Interviews:
January 7–8, 2026
Selected Respondent Announced:
January 21, 2026
Contact:
Angela Disponette, Office of the Purchasing Division, City of Frankfort, Kentucky; Phone (502) 352-2076; Email [email protected]
Issuing Organization:
City of Frankfort, Kentucky
Supporting Organizations:
Franklin County; Frankfort Tourist and Convention Commission; Downtown Frankfort, Inc.; Frankfort Area Chamber of Commerce; Kentucky Capital Development Corporation
Location:
Frankfort and Franklin County, Kentucky, USA
Document Type:
Request for Proposals (RFP)
Scope:
Riverfront visioning and strategic planning, including public outreach and steering committee involvement
Related Plans Referenced:
2009 Riverfront Development Plan; 2018 Downtown Master Plan; 2021 Blanton’s Landing Feasibility Study; 2011 Flood Mitigation Plan; 2013 Second Street Corridor Plan; 2016 Walk/Bike Master Plan; 2021 Parks, Recreation, and Historic Sites Master Plan; 2024 Land Use Comprehensive Plan
Deliverables:
Ten bound “Final Plans” and one electronic PDF; supporting materials (JPEGs or links); pricing valid 90 days from submission
Year:
2015
Region:
Victoria, Australia
Type of document:
Performance report
Organization:
Australian Health Practitioner Regulation Agency (AHPRA)
Scope:
Registration management, notifications management, compliance monitoring
Period:
October–December 2015
Target audience:
General public and stakeholders
Data coverage:
State and national levels (excludes NSW for notifications)
Health professions covered:
14 regulated health professions
Year:
2015
Region:
Northern Territory
Topic:
Health Practitioner Regulation
Document Type:
Performance Report
Organ/Institution:
Australian Health Practitioner Regulation Agency (AHPRA)
Author:
AHPRA
Target Audience:
Public, Health Practitioners, Regulatory Authorities
Period:
October–December 2015
Approval Date:
Not specified
Date of Last Changes:
Not specified
Year:
2021
Program Name:
Be Well Wednesdays (BWW)
Type of Document:
Program schedule and informational announcement
Format:
Online sessions via Zoom
Frequency:
Weekly on Wednesdays
Time:
12:10–1:00 pm Pacific / 3:10–4:00 pm Eastern
Organizing Entity:
National Association for Public Defense (NAPD)
Planning Team:
Jenny Andrews; Gina Pruski; Justin Heim; Tatiana Kline; John Lopez; Marilena David-Martin; Jeff Sherr
Target Audience:
Individuals working in public defense
Geographic Scope:
United States
Access:
Free and open drop-in sessions
Topics Covered:
Imposter Syndrome; Forgiveness Meditation; Establishing Boundaries to Maintain Balance; Healing Circle; Parenting During the Pandemic; Gratitude Exercise
Facilitators:
Tatiana Kline; John Lopez; Marilena David-Martin; Christine Start; Jessica Zimbelman; Justin Heim
Distribution Method:
Email subscription list for updates and materials
Contact Email:
[email protected]
Period Covered:
October 6, 2021 – December 1, 2021
Year:
2025
Region / City:
Northampton and surrounding area
Country:
United Kingdom
Deanery:
St John Fisher Deanery
Parish:
Parish of St Joseph, St Clare and Guardian Angels
Denomination:
Roman Catholic Church
Document type:
Parish newsletter and pastoral announcements
Topics:
parish life, funerals, charitable appeal, sacramental preparation, catechist formation, liturgical ministry training, parish community activities
Organizations mentioned:
CAFOD
Churches mentioned:
St Clare Church; St Joseph’s Church; St Francis & St Therese RC Church
Key events:
CAFOD Family Fast Day Appeal (3 October); Registration for First Confession and First Communion (8 October 2025); Catechist Formation sessions (October–November 2025); Readers formation programme (November–December 2025); Canon John’s Retirement Mass (26 September 2025)
Audience:
parishioners and members of the local Catholic community
Liturgical elements:
St John Fisher Deanery Prayer
Funeral notices:
Denis McGirr funeral (6 October); Margaret Elve funeral (17 October)
Communication format:
parish bulletin text including notices, appeals, event information, and community updates
Year:
2015
Region:
South Australia, Australia
Period covered:
October–December 2015
Subject:
Regulation of health practitioners and professional registration oversight
Document type:
Performance report
Organization:
Australian Health Practitioner Regulation Agency (AHPRA)
Related bodies:
National Boards of 14 health professions
Jurisdiction:
Australia (with state-level data for South Australia)
Legal framework:
National Law governing health practitioner regulation
Main activities covered:
Registration management; notifications management; statutory offence management; monitoring and compliance
Reporting scope:
Activities and performance metrics for a three-month period
Data coverage:
State and national statistics (excluding matters managed in New South Wales and certain complaints managed by the Office of the Health Ombudsman in Queensland)
Audience:
Public and stakeholders interested in health practitioner regulation
Feedback contact:
[email protected]
Year:
2016
Region / City:
UK
Topic:
Dermatology, Acute cutaneous drug reactions
Document Type:
Medical Guidelines
Organization:
British Association of Dermatologists (BAD)
Author:
Creamer, D., Walsh, S. A., Dziewulski, P., Smith, C. H.
Target Audience:
Healthcare professionals
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual description:
Medical guidelines for the identification and management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, including causes, treatment, and mortality prediction.
Note:
Year
Subject:
Dermatology
Document type:
Standardized letter of recommendation
Year:
2025
Region / City:
Malaysia
Topic:
Cosmeceuticals, Medicinal Plants, Ethnopharmacology, Skin Care
Document Type:
Article
Institution:
Lincoln University College
Author:
Idris Adewale Ahmed, Khadija Dia, Alhazmi Aseel Lafi A, Matab Jamal Elmahi Saeid
Target Audience:
Researchers, Industry Professionals, Regulatory Bodies
Period of Validity:
2000-2025
Approval Date:
28th November 2025
Revision Date:
27th November 2025
Keywords:
Medicinal Plants, Cosmeceuticals, Phytochemicals, Nanotechnology, Herbal Cosmetics, Skin Care, Regulation
Year:
2019
Organization:
Vita Health Group
Department:
Community Dermatology
Location:
Nationwide Remote and Clinic Based Opportunities
Job Title:
GPwsi/Consultant/Speciality Doctor Dermatology
Reporting to:
Consultant Dermatologist
Direct Reports:
None
Accountable to:
Consultant Dermatologist
Responsible to:
Consultant Dermatologist
Purpose:
Delivery of community dermatology services including patient assessment, treatment, and clinical governance
Roles and Responsibilities:
Clinical duties, training, supervision, equality, diversity & inclusion, clinical governance
Qualifications:
MRCGP, MBChB, Diploma in Dermatology or equivalent experience
Experience:
Managing dermatological patients in community or secondary care, use of dermatoscopy, minor procedures
Skills:
Autonomous work, complex decision making, diagnostic skills, long-term skin disease management
Personal Competencies:
Communication skills, teamwork, time management, patient care orientation
Travel Requirement:
Full driving license and vehicle access
Document Version:
V1.3
Date Published:
01/12/2023
Status:
PUBLISHED
Year:
2019–2021
Subject:
Dermatology and Urgent Care in Primary Care
Type of document:
Course reading list
Educational level:
Graduate nursing education
Module:
Week 11 and 12
Learning objectives:
WO1-4
Topics covered:
Skin complaints, infections, dermatitis, skin lesions, wounds, burns, bites, toxic and environmental exposures, dermatologic disorders across the lifespan
Instructional materials:
Required readings, optional readings, online modules, PowerPoint slides, instructional videos
Access requirements:
Online account required for American Academy of Dermatology curriculum
Name:
Dr Zamambo NC Mkhize
Telephone:
033 395 4738
Email:
[email protected]
Campus:
Medical campus
Designation:
Acting Head of Dermatology
Institution:
Edendale Hospital
Academic Affiliation:
UKZN School of Clinical Medicine (honorary lecturer)
Education:
Undergraduate studies at UKZN Medical School
Specialization:
Dermatology
Research Interests:
Skin diseases, HIV/AIDS-related dermatology
Professional Experience:
Private practice in Pietermaritzburg, establishment of dermatology department at Edendale Hospital
Community Involvement:
Rural outreach programs in South Africa
Target Population:
Patients from KwaZulu-Natal, Eastern Cape, and Lesotho
Career Goals:
Leadership development in dermatology